Zhangzhou Pientzehuang Pharmaceutical., Ltd Logo

Zhangzhou Pientzehuang Pharmaceutical., Ltd

600436.SS

(4.2)
Stock Price

246,60 CNY

17.76% ROA

21.9% ROE

55.27x PER

Market Cap.

164.584.877.600,00 CNY

8.25% DER

0.85% Yield

28.02% NPM

Zhangzhou Pientzehuang Pharmaceutical., Ltd Stock Analysis

Zhangzhou Pientzehuang Pharmaceutical., Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (23.26%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a low debt to equity ratio (7%), which means it has a small amount of debt compared to the ownership it holds

4 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

5 Net Profit Growth

Throughout the past five years, this company has consistently experienced net profit growth, indicating a strong financial performance and making it an attractive investment prospect.

6 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

7 Dividend Growth

The company's dividend growth has consistently increased every year in the last five years, indicating a strong track record of positive returns for investors.

8 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

9 Buffet Intrinsic Value

The company's stock seems undervalued (1.085) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

10 PBV

The stock's elevated P/BV ratio (11.55x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

11 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Buy

Zhangzhou Pientzehuang Pharmaceutical., Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Revenue
Year Revenue Growth
2000 183.921.549
2001 193.893.836 5.14%
2002 212.033.133 8.55%
2003 213.593.967 0.73%
2004 253.486.070 15.74%
2005 418.820.927 39.48%
2006 522.205.339 19.8%
2007 593.069.218 11.95%
2008 649.743.490 8.72%
2009 694.749.846 6.48%
2010 867.314.583 19.9%
2011 1.021.565.728 15.1%
2012 1.171.153.738 12.77%
2013 1.395.868.518 16.1%
2014 1.453.869.771 3.99%
2015 1.885.674.673 22.9%
2016 2.308.954.269 18.33%
2017 3.713.953.975 37.83%
2018 4.766.156.893 22.08%
2019 5.722.273.431 16.71%
2020 6.510.781.957 12.11%
2021 8.021.550.451 18.83%
2022 8.694.001.504 7.73%
2023 10.218.404.227 14.92%
2023 9.977.863.681 -2.41%
2024 9.918.896.684 -0.59%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Research and Development Expenses
Year Research and Development Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 8.593.467 100%
2011 14.918.095 42.4%
2012 23.198.294 35.69%
2013 46.991.515 50.63%
2014 45.179.195 -4.01%
2015 49.611.625 8.93%
2016 66.945.255 25.89%
2017 139.808.686 52.12%
2018 100.814.212 -38.68%
2019 119.432.087 15.59%
2020 97.551.620 -22.43%
2021 199.510.670 51.1%
2022 230.034.488 13.27%
2023 256.079.650 10.17%
2023 207.185.559 -23.6%
2024 355.237.676 41.68%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Zhangzhou Pientzehuang Pharmaceutical., Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 20.481.171
2001 18.135.465 -12.93%
2002 23.433.274 22.61%
2003 31.354.185 25.26%
2004 71.326.249 56.04%
2005 42.150.388 -69.22%
2006 37.742.604 -11.68%
2007 39.010.032 3.25%
2008 44.134.838 11.61%
2009 54.792.376 19.45%
2010 16.784.019 -226.46%
2011 19.089.752 12.08%
2012 20.098.838 5.02%
2013 22.245.524 9.65%
2014 18.380.497 -21.03%
2015 27.394.191 32.9%
2016 29.091.852 5.84%
2017 -31.176.332 193.31%
2018 51.526.867 160.51%
2019 47.391.470 -8.73%
2020 71.407.653 33.63%
2021 64.746.151 -10.29%
2022 51.023.894 -26.89%
2023 919.416.317 94.45%
2023 62.642.323 -1367.72%
2024 306.755.980 79.58%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Zhangzhou Pientzehuang Pharmaceutical., Ltd EBITDA
Year EBITDA Growth
2000 81.951.416
2001 88.687.644 7.6%
2002 98.274.057 9.75%
2003 98.993.110 0.73%
2004 87.079.263 -13.68%
2005 142.677.127 38.97%
2006 137.633.260 -3.66%
2007 145.675.858 5.52%
2008 187.173.317 22.17%
2009 169.309.404 -10.55%
2010 228.959.007 26.05%
2011 336.586.488 31.98%
2012 455.666.372 26.13%
2013 568.224.881 19.81%
2014 571.897.970 0.64%
2015 615.275.230 7.05%
2016 702.740.863 12.45%
2017 1.038.354.574 32.32%
2018 1.452.893.908 28.53%
2019 1.741.993.943 16.6%
2020 2.072.250.286 15.94%
2021 3.045.984.035 31.97%
2022 3.120.577.848 2.39%
2023 4.219.828.674 26.05%
2023 3.357.187.860 -25.7%
2024 3.539.557.876 5.15%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Gross Profit
Year Gross Profit Growth
2000 118.363.585
2001 123.009.511 3.78%
2002 137.541.174 10.57%
2003 143.170.031 3.93%
2004 170.459.647 16.01%
2005 203.697.340 16.32%
2006 189.868.091 -7.28%
2007 218.039.066 12.92%
2008 241.521.842 9.72%
2009 264.348.539 8.64%
2010 334.238.833 20.91%
2011 465.176.218 28.15%
2012 619.825.831 24.95%
2013 761.717.893 18.63%
2014 725.711.472 -4.96%
2015 886.368.397 18.13%
2016 1.130.133.181 21.57%
2017 1.606.761.142 29.66%
2018 2.021.798.879 20.53%
2019 2.531.330.181 20.13%
2020 2.940.223.947 13.91%
2021 4.068.570.528 27.73%
2022 3.968.147.303 -2.53%
2023 5.230.537.565 24.14%
2023 4.518.497.475 -15.76%
2024 2.230.661.228 -102.56%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Net Profit
Year Net Profit Growth
2000 50.053.140
2001 52.162.214 4.04%
2002 58.788.450 11.27%
2003 60.478.126 2.79%
2004 41.773.649 -44.78%
2005 86.398.283 51.65%
2006 81.908.175 -5.48%
2007 95.188.986 13.95%
2008 140.869.750 32.43%
2009 129.663.236 -8.64%
2010 194.131.768 33.21%
2011 254.867.961 23.83%
2012 348.529.663 26.87%
2013 429.768.408 18.9%
2014 438.828.802 2.06%
2015 466.676.722 5.97%
2016 536.131.906 12.95%
2017 807.018.675 33.57%
2018 1.142.932.917 29.39%
2019 1.374.376.823 16.84%
2020 1.671.518.667 17.78%
2021 2.431.899.933 31.27%
2022 2.472.344.731 1.64%
2023 3.455.245.445 28.45%
2023 2.797.351.515 -23.52%
2024 2.988.129.948 6.38%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 100%
2018 2 0%
2019 2 50%
2020 3 0%
2021 4 50%
2022 4 0%
2023 6 20%
2023 5 -25%
2024 5 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Free Cashflow
Year Free Cashflow Growth
2001 54.199.970
2002 95.678.152 43.35%
2003 16.792.597 -469.76%
2004 87.918.195 80.9%
2005 34.518.505 -154.7%
2006 41.992.545 17.8%
2007 -46.427.777 190.45%
2008 -45.929.459 -1.08%
2009 99.852.908 146%
2010 166.515.198 40.03%
2011 197.386.168 15.64%
2012 7.173.138 -2651.74%
2013 127.792.226 94.39%
2014 238.634.628 46.45%
2015 226.646.832 -5.29%
2016 303.564.613 25.34%
2017 625.065.237 51.43%
2018 538.075.213 -16.17%
2019 -944.808.168 156.95%
2020 1.048.065.529 190.15%
2021 370.105.546 -183.18%
2022 6.697.656.897 94.47%
2023 991.997.424 -575.17%
2023 2.088.873.972 52.51%
2024 -164.415.784 1370.48%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Operating Cashflow
Year Operating Cashflow Growth
2001 65.843.403
2002 105.446.586 37.56%
2003 32.356.938 -225.89%
2004 98.671.516 67.21%
2005 69.055.604 -42.89%
2006 50.703.654 -36.19%
2007 60.038.070 15.55%
2008 12.573.378 -377.5%
2009 129.519.043 90.29%
2010 205.410.719 36.95%
2011 232.950.354 11.82%
2012 162.398.128 -43.44%
2013 274.336.209 40.8%
2014 264.499.645 -3.72%
2015 305.510.311 13.42%
2016 394.537.198 22.56%
2017 676.933.316 41.72%
2018 612.310.818 -10.55%
2019 -879.372.169 169.63%
2020 1.467.076.541 159.94%
2021 462.272.404 -217.36%
2022 6.873.030.580 93.27%
2023 1.010.925.377 -579.88%
2023 2.230.746.685 54.68%
2024 -149.390.851 1593.23%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Capital Expenditure
Year Capital Expenditure Growth
2001 11.643.432
2002 9.768.434 -19.19%
2003 15.564.341 37.24%
2004 10.753.320 -44.74%
2005 34.537.098 68.86%
2006 8.711.109 -296.47%
2007 106.465.847 91.82%
2008 58.502.837 -81.98%
2009 29.666.134 -97.2%
2010 38.895.520 23.73%
2011 35.564.186 -9.37%
2012 155.224.989 77.09%
2013 146.543.983 -5.92%
2014 25.865.016 -466.57%
2015 78.863.479 67.2%
2016 90.972.584 13.31%
2017 51.868.079 -75.39%
2018 74.235.604 30.13%
2019 65.435.999 -13.45%
2020 419.011.012 84.38%
2021 92.166.858 -354.62%
2022 175.373.683 47.45%
2023 18.927.953 -826.53%
2023 141.872.713 86.66%
2024 15.024.933 -844.25%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Equity
Year Equity Growth
2000 141.351.190
2001 146.018.764 3.2%
2002 154.807.214 5.68%
2003 553.586.765 72.04%
2004 539.081.543 -2.69%
2005 608.069.377 11.35%
2006 621.093.996 2.1%
2007 758.850.736 18.15%
2008 752.093.235 -0.9%
2009 857.185.639 12.26%
2010 1.083.862.749 20.91%
2011 1.188.985.850 8.84%
2012 1.555.552.077 23.57%
2013 2.592.241.172 39.99%
2014 2.987.299.944 13.22%
2015 3.303.325.460 9.57%
2016 3.750.748.994 11.93%
2017 4.425.234.006 15.24%
2018 5.307.617.549 16.62%
2019 6.969.757.513 23.85%
2020 8.256.555.529 15.59%
2021 10.136.749.206 18.55%
2022 11.823.939.237 14.27%
2023 13.920.497.525 15.06%
2023 13.559.236.278 -2.66%
2024 14.244.841.776 4.81%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Assets
Year Assets Growth
2000 258.676.820
2001 270.361.502 4.32%
2002 325.794.975 17.01%
2003 594.988.599 45.24%
2004 558.773.863 -6.48%
2005 693.627.380 19.44%
2006 730.619.749 5.06%
2007 970.876.443 24.75%
2008 1.070.538.280 9.31%
2009 1.284.539.847 16.66%
2010 1.446.829.315 11.22%
2011 1.568.680.742 7.77%
2012 2.230.774.620 29.68%
2013 3.259.294.355 31.56%
2014 3.649.637.158 10.7%
2015 4.054.922.388 9.99%
2016 5.037.818.928 19.51%
2017 5.648.277.442 10.81%
2018 6.657.757.885 15.16%
2019 8.810.796.390 24.44%
2020 10.205.569.714 13.67%
2021 12.495.334.742 18.32%
2022 14.603.844.518 14.44%
2023 17.080.413.435 14.5%
2023 16.095.502.214 -6.12%
2024 17.047.043.335 5.58%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Liabilities
Year Liabilities Growth
2000 117.325.629
2001 124.342.738 5.64%
2002 170.987.761 27.28%
2003 41.401.832 -313%
2004 19.692.320 -110.24%
2005 85.558.002 76.98%
2006 109.525.753 21.88%
2007 212.025.705 48.34%
2008 318.445.045 33.42%
2009 427.354.207 25.48%
2010 362.966.566 -17.74%
2011 379.694.891 4.41%
2012 675.222.542 43.77%
2013 667.053.182 -1.22%
2014 662.337.213 -0.71%
2015 751.596.928 11.88%
2016 1.287.069.933 41.6%
2017 1.223.043.435 -5.24%
2018 1.350.140.334 9.41%
2019 1.841.038.876 26.66%
2020 1.949.014.183 5.54%
2021 2.358.585.534 17.37%
2022 2.779.905.281 15.16%
2023 3.142.248.831 11.53%
2023 2.536.265.936 -23.89%
2024 2.780.265.690 8.78%

Zhangzhou Pientzehuang Pharmaceutical., Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
17.62
Net Income per Share
4.94
Price to Earning Ratio
55.27x
Price To Sales Ratio
15.48x
POCF Ratio
133.57
PFCF Ratio
145.87
Price to Book Ratio
12.04
EV to Sales
14.77
EV Over EBITDA
43.58
EV to Operating CashFlow
127.39
EV to FreeCashFlow
139.12
Earnings Yield
0.02
FreeCashFlow Yield
0.01
Market Cap
164,58 Bil.
Enterprise Value
156,97 Bil.
Graham Number
50.16
Graham NetNet
15.78

Income Statement Metrics

Net Income per Share
4.94
Income Quality
0.41
ROE
0.22
Return On Assets
0.17
Return On Capital Employed
0.24
Net Income per EBT
0.83
EBT Per Ebit
1.03
Ebit per Revenue
0.33
Effective Tax Rate
0.16

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.03
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.41
Operating Profit Margin
0.33
Pretax Profit Margin
0.34
Net Profit Margin
0.28

Dividends

Dividend Yield
0.01
Dividend Yield %
0.85
Payout Ratio
0.98
Dividend Per Share
2.32

Operating Metrics

Operating Cashflow per Share
2.04
Free CashFlow per Share
1.87
Capex to Operating CashFlow
0.08
Capex to Revenue
0.01
Capex to Depreciation
2.48
Return on Invested Capital
0.2
Return on Tangible Assets
0.18
Days Sales Outstanding
38.02
Days Payables Outstanding
27.24
Days of Inventory on Hand
262.58
Receivables Turnover
9.6
Payables Turnover
13.4
Inventory Turnover
1.39
Capex per Share
0.17

Balance Sheet

Cash per Share
15,25
Book Value per Share
23,65
Tangible Book Value per Share
23.18
Shareholders Equity per Share
22.66
Interest Debt per Share
1.93
Debt to Equity
0.08
Debt to Assets
0.07
Net Debt to EBITDA
-2.11
Current Ratio
5.99
Tangible Asset Value
13,99 Bil.
Net Current Asset Value
12,35 Bil.
Invested Capital
13732316095
Working Capital
12,60 Bil.
Intangibles to Total Assets
0.02
Average Receivables
1,12 Bil.
Average Payables
0,52 Bil.
Average Inventory
4209650596
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Zhangzhou Pientzehuang Pharmaceutical., Ltd Dividends
Year Dividends Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 100%
2015 1 0%
2016 1 0%
2017 0 0%
2018 0 0%
2019 1 0%
2020 1 0%
2021 1 0%
2022 1 100%
2023 1 0%
2024 2 50%

Zhangzhou Pientzehuang Pharmaceutical., Ltd Profile

About Zhangzhou Pientzehuang Pharmaceutical., Ltd

Zhangzhou Pientzehuang Pharmaceutical., Ltd engages in the manufacture and sale of Chinese medicines under the Pien Tze Huang brand in China and internationally. The company's products include medicines and health products, cosmetics, daily chemicals, medical apparatus and instruments, and health foods. The company is based in Zhangzhou, China. Zhangzhou Pientzehuang Pharmaceutical., Ltd is a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd.

CEO
Mr. Jin Ming Huang
Employee
2.789
Address
Pien Tze Huang Building
Zhangzhou, 363000

Zhangzhou Pientzehuang Pharmaceutical., Ltd Executives & BODs

Zhangzhou Pientzehuang Pharmaceutical., Ltd Executives & BODs
# Name Age
1 Mr. Cong Sheng Liu
Deputy GM & Director
70
2 Mr. Jin Cheng Chen
Chairman of the Supervisory Committee
70
3 Ms. Fei Hong
Chief Engineer
70
4 Mr. Jin Ming Huang
GM & Director
70
5 Mr. Haipeng Yang
Chief Accountant & Director
70

Zhangzhou Pientzehuang Pharmaceutical., Ltd Competitors